Upfront triple therapy with parenteral prostanoid as a bridge to balloon pulmonary angioplasty in severe chronic thromboembolic pulmonary hypertension

Nicolas Piliero; Muriel Salvat; Mathieu Finas; Florence Curioz; Julie Traclet; Kaïs Ahmad; Laurent Bertoletti; Estelle Vautrin; Hélène Bouvaist; Bruno Degano

doi:10.1183/23120541.00085-2024

Upfront triple therapy with parenteral prostanoid as a bridge to balloon pulmonary angioplasty in severe chronic thromboembolic pulmonary hypertension

ERJ Open Res. 2024 Mar 4;10(2):00085-2024. doi: 10.1183/23120541.00085-2024. eCollection 2024 Mar.

Authors

Affiliations

¹ Service de Cardiologie, CHU Grenoble Alpes, Grenoble, France.
² Service de Radiologie, CHU Grenoble Alpes, Grenoble, France.
³ Service de Pneumologie, Centre de Référence des Maladies Pulmonaires Rares, Hôpital Louis-Pradel, Université de Lyon, Lyon, France.
⁴ Service de Médecine Vasculaire et Thérapeutique, CHU de St-Etienne, Saint-Etienne, France.
⁵ INSERM, UMR1059, Équipe Dysfonction Vasculaire et Hémostase, Université Jean-Monnet, Saint-Etienne, France.
⁶ INSERM, CIC-1408, CHU Saint-Etienne, Saint-Etienne, France.
⁷ INSERM U1300, Laboratoire HP2, Université Grenoble Alpes, Grenoble, France.
⁸ Service de Pneumologie, CHU Grenoble Alpes, Grenoble, France.

Abstract

In patients with very severe CTEPH eligible for BPA, it is possible to achieve major haemodynamic improvement with upfront triple PH therapy including epoprostenol and then to perform angioplasties https://bit.ly/3vZZvib.